http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102304108-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate | 2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102304108-B1 |
| titleOfInvention | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
| abstract | - non-Hodgkin's lymphoma (NHL), in particular primary, secondary, relapsed, refractory, delayed or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) , for the manufacture of a medicament for the treatment or prophylaxis of marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), metamorphic lymphoma (TL), or peripheral T-cell lymphoma (PTCL) , a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a pharmaceutical composition comprising it as the sole active agent, or a) said compound or a pharmaceutical composition comprising said compound and b) one or more additional use of combinations of active agents; n n n - a) a combination of said compound with b) at least one further active agent; - non-Hodgkin's lymphoma (NHL), in particular primary, secondary, relapsed, refractory, delayed or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) , marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), metamorphic lymphoma (TL), or peripheral T-cell lymphoma (PTCL) as the only active agent. pharmaceutical compositions that - a pharmaceutical composition comprising a combination of a) said compound and b) at least one further active agent; - expression of PI3K isoforms, BTK and IKK, BCR, for predicting sensitivity and/or resistance to said compounds in cancer patients and providing an evidence-based synergistic combination as defined herein for increasing sensitivity and/or overcoming resistance use of biomarkers involved in activation, activation of BCR downstream of the NFκB pathway, alteration of c-Myc, EZH2; and - a method for determining the level of one or more components of the PI3K isoform, expression of BTK and IKK, BCR activation, BCR downstream activation of the NFκB pathway, c-Myc, EZH2. |
| priorityDate | 2013-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1336.